Asthma Triggers And Managing Articles & Analysis: Older
48 news found
Bedfont® Scientific Ltd., world leaders in breath analysis with over 47 years of knowledge in designing and manufacturing medical breath analysis devices, welcomes the recent update to the National Institute for Health and Care Excellence (NICE) guidelines on asthma management. Bedfont® manufactures the NObreath® Fractional exhaled Nitric Oxide (FeNO) device, which aids in diagnosing ...
Vitalograph is proud to announce that it a FeNO by NIOX® UK channel partner. Spirometry and FeNO present physicians with complementary diagnostic data to inform asthma care pathways. NIOX VERO® is non-invasive, simple-to-use, and provides rapid standardised FeNO measurements. It is a point-of-care device for assessing airway inflammation in patients with respiratory problems. With over ...
There are many known asthma triggers, but one of the more common ones is exposure to elevated levels of mold. ...
Circassia Pharmaceuticals plc, (“Circassia” or “the Company”; LSE: CIR) announces that the Board has concluded that it is in the best interests of the Company to terminate the development and commercialisation agreement between the Company and AstraZeneca UK Limited, a subsidiary of AstraZeneca plc (LSE/STO/NYSE: AZN) (AstraZeneca) for the U.S. commercial rights to ...
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US launch of Duaklir® for the maintenance treatment of chronic obstructive pulmonary disease (COPD) at the American College of Chest Physicians’ CHEST Annual Meeting 2019, which is currently ongoing in New ...
Abionic SA, the developer of proprietary disruptive nanotechnology based rapid diagnostic solutions, and Genentech, a member of the Roche Group, announced today a strategic agreement to develop and provide an In Vitro Diagnostic (IVD) Asthma Test Panel using Abionic’s POC abioSCOPE® platform in the United States. Abionic’s POC abioSCOPE®, a compact, ultra-fast medical device ...
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty biopharmaceutical company focused on respiratory disease, today announces the appointment of Jonathan Emms to the newly-created role of Chief Operating Officer (COO). As COO he will further strengthen Circassia’s commercial focus and lead the Company’s global commercial strategy ...
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*. The ASCENT study was conducted in patients with moderate-to-very severe chronic obstructive ...
Data showing reduction in COPD exacerbations and no increase in major cardiovascular events vs placebo added to label – – Tudorza® is the only product in its class with these data in the label Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the US ...
” Option exercise Under the terms of Circassia’s agreement with AstraZeneca, completion of the option exercise will trigger a payment of $5 million. A deferred Tudorza® option payment of $20 million will be payable upon approval of Duaklir® (aclidinium / formoterol), in addition to deferred consideration of $100 million due under the companies’ ...
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces that the United States Food and Drug Administration (FDA) has confirmed it has completed its validation for completeness, and accepted for filing and review, the previously submitted Duaklir® New Drug Application ...
Duaklir® NDA for treatment of chronic obstructive pulmonary disease (COPD) Tudorza® sNDA for inclusion of COPD exacerbation reduction and cardiovascular safety data in label Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the submission of a New Drug ...
Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the presentation of positive clinical data from the Tudorza® Pressair® phase IV ASCENT study and Duaklir® Pressair® phase III AMPLIFY study at the American Thoracic Society (ATS) 2018 International ...
The inflammation also causes the airways of the lungs to become especially sensitive to a variety of asthma triggers. The particular trigger or triggers and the severity of symptoms can differ for each person with the disease. ...
Managing students’ asthma and limiting their exposure to asthma triggers is a challenge in any school district. ...
Their newest production discusses the impact asthma has on students and identifying asthma triggers in schools to help manage the condition. “As recently as 2015, the CDC reports that 1 in 12 children had asthma,” said Paul Cochrane, President of Cochrane and Associates and the IAQ Video Network. ...
Fortunately, there are steps business owners and managers can take to manage asthma in the workplace. A key component of this is to identify occupational asthma triggers so that steps can be taken to eliminate or minimize exposure risks. ...
People with the condition are often exposed to numerous known asthma triggers in their homes, schools, and work environments. Occupational asthma, also referred to as work-related asthma, is the most common occupational lung disease in the United States. ...
Although there is no cure for asthma yet, asthma can be controlled through medical treatment and management of environmental triggers. ...
Air pollution, dust mites, secondhand smoke, mold, pests, and pet dander can trigger asthma attacks. Work with your doctor to identify and avoid your personal asthma triggers, since asthma sufferers are affected differently. ...